IDEAS home Printed from https://ideas.repec.org/r/pra/mprapa/15965.html
   My bibliography  Save this item

Global Competitiveness in Pharmaceuticals: A European Perspective

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Frances Ruane & Xiaoheng Zhang, 2007. "Where do MNEs Expand Production: Location Choices of the Pharmaceutical Industry in Europe after 1992," Papers WP211, Economic and Social Research Institute (ESRI).
  2. Antonio Cabrales & Sergi Jiménez‐Martín, 2013. "The Determinants Of Pricing In Pharmaceuticals: Are Us Prices Really So High?," Health Economics, John Wiley & Sons, Ltd., vol. 22(11), pages 1377-1397, November.
  3. Chris van Egeraat & Proinnsias Breathnach, 2012. "The Drivers of Transnational Subsidiary Evolution: The Upgrading of Process R&D in the Irish Pharmaceutical Industry," Regional Studies, Taylor & Francis Journals, vol. 46(9), pages 1153-1167, October.
  4. Jason Owen-Smith & Massimo Riccaboni & Fabio Pammolli & Walter W. Powell, 2002. "A Comparison of U.S. and European University-Industry Relations in the Life Sciences," Management Science, INFORMS, vol. 48(1), pages 24-43, January.
  5. Havas, Attila, 2010. "Diversity in firms’ innovation strategies and activities: Main findings of interviews and implications in the context of the Hungarian national," MPRA Paper 55852, University Library of Munich, Germany.
  6. Herrmann, Andrea M., 2008. "On the discrepancies between macro and micro level identification of competitive strategies," MPIfG Discussion Paper 08/6, Max Planck Institute for the Study of Societies.
  7. Antonio Cabrales & Sergi Jiménez-Martín, 2007. "The determinants of pricing in pharmaceuticals: Are U.S. prices really higher than those of Canada?," Economics Working Papers 1032, Department of Economics and Business, Universitat Pompeu Fabra.
  8. Martin Backfisch, 2017. "Have Pharmaceutical R&D Project Success Rates Decreased? A Critical Review and New Empirical Results," MAGKS Papers on Economics 201746, Philipps-Universität Marburg, Faculty of Business Administration and Economics, Department of Economics (Volkswirtschaftliche Abteilung).
  9. Desmet, Klaus & Kujal, Praveen & Lobo, Felix, 2004. "Implementing R&D policies: an analysis of Spain's pharmaceutical research program," Research Policy, Elsevier, vol. 33(10), pages 1493-1507, December.
  10. Peter Kotzian, 2004. "Pharmaceutical R&D in the Setting of Incomplete European Integration," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 11(2), pages 175-195.
  11. Joseph Golec & John Vernon, 2010. "Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms," PharmacoEconomics, Springer, vol. 28(8), pages 615-628, August.
  12. Gianluca Baio & Laura Magazzini & Antonio Nicita & Fabio Pammolli & Massimo Riccaboni, 2003. "Il Decreto DL 15/04/2002, n. 63 sul Contenimento della Spesa Farmaceutica - Impatto sull'Industria e Distorsioni nel Funzionamento del Mercato," Working Papers CERM 0-2003, Competitività, Regole, Mercati (CERM).
  13. Magazzini, Laura & Pammolli, Fabio & Riccaboni, Massimo, 2004. "Dynamic Competition in Pharmaceuticals: Patent Expiry, Generic Penetration, and Industry Structure," MPRA Paper 15968, University Library of Munich, Germany.
  14. Chiara Bonassi & Fabio Pammolli & Massimo Riccaboni & Nicola Carmine Salerno, 2007. "Regolazione, innovazione e ciclo di vita dei prodotti - per una riforma del pricing al lancio e della governance della spesa nella farmaceutica pubblica," Working Papers CERM 02-2007, Competitività, Regole, Mercati (CERM).
  15. Peter Kotzian, 2002. "Stuck in the Middle: Welfare Effects of the European Pharmaceutical Markets' Incomplete Integration and a Possible Remedy," MZES Working Papers 59, MZES.
  16. Michael Schlander & Karla Hernandez-Villafuerte & Chih-Yuan Cheng & Jorge Mestre-Ferrandiz & Michael Baumann, 2021. "How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment," PharmacoEconomics, Springer, vol. 39(11), pages 1243-1269, November.
  17. Martin Backfisch, 2018. "The Development of Firm Size and Innovativeness in the Pharmaceutical industry between 1989 and 2010," MAGKS Papers on Economics 201813, Philipps-Universität Marburg, Faculty of Business Administration and Economics, Department of Economics (Volkswirtschaftliche Abteilung).
  18. Seiko Arai, 2016. "Absorptive Capability of Japanese and European MNCs: Balance between Autonomy and Control of R&D Subsidiaries in the US," GRIPS Discussion Papers 16-18, National Graduate Institute for Policy Studies.
  19. Herrmann, Andrea M., 2008. "Choosing and successfully sustaining competitive strategies in the European pharmaceutical industry," MPIfG Discussion Paper 08/9, Max Planck Institute for the Study of Societies.
  20. Paola Criscuolo, 2003. "Reverse Technology Transfer: A Patent Citation Analysis of the European Chemical and Pharmaceutical Sectors," SPRU Working Paper Series 107, SPRU - Science Policy Research Unit, University of Sussex Business School.
  21. repec:dau:papers:123456789/7972 is not listed on IDEAS
  22. Frances Ruane & Xiaoheng Zhang, 2007. "Location Choices of the Pharmaceutical Industry in Europe after 1992," The Institute for International Integration Studies Discussion Paper Series iiisdp220, IIIS.
  23. Dominique Kleyn & Richard Kitney & Rifat A. Atun, 2007. "Partnership And Innovation In The Life Sciences," International Journal of Innovation Management (ijim), World Scientific Publishing Co. Pte. Ltd., vol. 11(02), pages 323-347.
  24. Laura Magazzini & Fabio Pammolli & Massimo Riccaboni, 2004. "Dynamic competition in pharmaceuticals," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(2), pages 175-182, May.
  25. Antonio Cabrales, 2003. "Pharmaceutical generics, vertical product differentiation and public policy," Economics Working Papers 662, Department of Economics and Business, Universitat Pompeu Fabra.
  26. Herrmann, Andrea M. & Peine, Alexander, 2011. "When 'national innovation system' meet 'varieties of capitalism' arguments on labour qualifications: On the skill types and scientific knowledge needed for radical and incremental product innovations," Research Policy, Elsevier, vol. 40(5), pages 687-701, June.
  27. García, Clara Eugenia, 2003. "Implementing R and D policies : an analysis of Spain's pharmaceutical research program," UC3M Working papers. Economics we035923, Universidad Carlos III de Madrid. Departamento de Economía.
  28. Gilsing, Victor & Nooteboom, Bart, 2006. "Exploration and exploitation in innovation systems: The case of pharmaceutical biotechnology," Research Policy, Elsevier, vol. 35(1), pages 1-23, February.
  29. Pammolli, Fabio & Riccaboni, Massimo, 2004. "Market Structure and Drug Innovation," MPRA Paper 16212, University Library of Munich, Germany.
  30. Heneric, Oliver & Engel, Dirk & Champenois, Claire, 2004. "The Birth of German Biotechnology Industry: Did Venture Capital run the Show?," ZEW Discussion Papers 04-09, ZEW - Leibniz Centre for European Economic Research.
  31. Bernard Guilhon, 2004. "Markets for knowledge: problems, scope, and economic implications," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 13(2), pages 165-181.
  32. Abdelilah Hamdouch & Feng He, 2009. "R&D offshoring and clustering dynamics in pharmaceuticals and biotechnology: key features and insights from the Chinese case," Journal of Innovation Economics, De Boeck Université, vol. 0(2), pages 95-117.
  33. Casper, Steven & Matraves, Catherine, 2003. "Institutional frameworks and innovation in the German and UK pharmaceutical industry," Research Policy, Elsevier, vol. 32(10), pages 1865-1879, December.
  34. Anna Giunta & Filippo M. Pericoli & Eleonora Pierucci, 2016. "University–Industry collaboration in the biopharmaceuticals: the Italian case," The Journal of Technology Transfer, Springer, vol. 41(4), pages 818-840, August.
  35. Fabio Pammolli & Armando Rungi, 2016. "Access to Medicines and European Market Integration," Working Papers 01/2016, IMT School for Advanced Studies Lucca, revised Jan 2016.
  36. Eleonora Pierucci, 2015. "University-industry linkages. Among italian regions: a supply-demand analysis," RIVISTA DI ECONOMIA E STATISTICA DEL TERRITORIO, FrancoAngeli Editore, vol. 2015(2), pages 5-33.
  37. Archibugi, Daniele & Bizzarri, Kim, 2004. "Committing to vaccine R&D: a global science policy priority," Research Policy, Elsevier, vol. 33(10), pages 1657-1671, December.
  38. Franco Malerba & Luigi Orsenigo, 2000. "Towards a History Friendly Model of Innovation, Market Structure and Regulation in the Dynamics of the Pharmaceutical Industry: the Age of Random Screening," KITeS Working Papers 124, KITeS, Centre for Knowledge, Internationalization and Technology Studies, Universita' Bocconi, Milano, Italy, revised Jan 2001.
  39. Christine de Mazières & Valérie Paris, 2004. "La régulation de l’industrie pharmaceutique," Revue d'Économie Financière, Programme National Persée, vol. 76(3), pages 241-265.
  40. Criscuolo, Paola, 2002. "Reverse Technology Transfer: A Patent Citation Analysis of the European Chemical and Pharmaceutical sectors," Research Memorandum 036, Maastricht University, Maastricht Economic Research Institute on Innovation and Technology (MERIT).
  41. Archibugi, Daniele & Bizzarri, Kim, 2004. "Committing to vaccine R&D: a global science policy priority," Research Policy, Elsevier, vol. 33(10), pages 1657-1671, December.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.